Provided by Tiger Fintech (Singapore) Pte. Ltd.

Allogene Therapeutics Inc.

1.57
-0.0400-2.48%
Pre-market: 1.570.00000.00%05:43 EDT
Volume:1.58M
Turnover:2.49M
Market Cap:341.11M
PE:-1.19
High:1.62
Open:1.61
Low:1.54
Close:1.61
Loading ...

Allogene announces Phase 1 data on ALLO-316 in advanced RCC

TIPRANKS
·
07 Nov 2024

Allogene Therapeutics Inc - Allo-316 Demonstrated a Manageable Safety Profile

THOMSON REUTERS
·
07 Nov 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of Allo-316 in Heavily Pretreated Patients With Advanced Renal Cell Carcinoma at SITC and Ikcs

THOMSON REUTERS
·
07 Nov 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

GlobeNewswire
·
07 Nov 2024

Allogene Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
06 Nov 2024

Allogene Therapeutics to present data on ALLO-316 at IKCS, SITC meetings

TIPRANKS
·
05 Nov 2024

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

GlobeNewswire
·
05 Nov 2024

Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know

Zacks
·
31 Oct 2024

BRIEF-Allogene Therapeutics To Report Third Quarter 2024 Financial Results And Provide Business Update

Reuters
·
30 Oct 2024

Allogene Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
30 Oct 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

THOMSON REUTERS
·
30 Oct 2024

Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma

MT Newswires Live
·
29 Oct 2024

We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully

Simply Wall St.
·
29 Oct 2024

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Allo-316, an Allocar T™ Investigational Product for Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (Rcc)

THOMSON REUTERS
·
29 Oct 2024

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

GlobeNewswire
·
29 Oct 2024